Skip to content

Pilot Study Assessing the Feasibility of Treating Foot Drop With the Neurostep™ System.

Pilot Feasibility Study of the Neurostep™ System in Subjects With Gait Disorder Secondary to CNS Lesion.

Status
Completed
Phases
Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00860210
Enrollment
14
Registered
2009-03-12
Start date
2007-10-31
Completion date
2010-03-31
Last updated
2010-04-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Craniocerebral Trauma, Stroke

Brief summary

This pilot feasibility study is assessing the safety and technical performance of the Neurostep™ System for the restoration of independent gait in subjects with gait disorder (i.e. foot drop) secondary to a CNS lesion (e.g. stroke).

Detailed description

The Neurostep™ System is a neurostimulation investigational medical device. The entire system is designed to be implanted into the subject's leg via a surgical procedure, during which electrodes are attached to the peripheral nerves responsible for sensing and stimulating the proper muscles that lift the foot during normal walking.

Interventions

DEVICENeurostep™ System

The Neurostep™ System is a neurostimulation investigational medical device. The entire system is designed to be implanted into the subject's leg via a surgical procedure, during which electrodes are attached to the peripheral nerves responsible for sensing and stimulating the proper muscles that lift the foot during normal walking.

Sponsors

Neurostream Technologies G.P.
Lead SponsorINDUSTRY

Study design

Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* Diagnosed with a unilateral gait disorder as a result of a specified CNS lesion (e.g., stroke)with stable neurological deficit for at least 6 months * Medically stable, able to and agree to undergo a surgery * Able to stand and walk at least 5 meters * Agree to attend frequent study scheduled visits * Able to provide verbal or written feedback * Have provided written informed consent * Have intact tibial and common peroneal nerves

Exclusion criteria

* Pregnant or nursing women * Medically insufficiently stable to undergo surgery * Poor range of motion of affected ankle or fixed ankle * Foreseen need for Magnetic Resonance Imaging (MRI) * Significant mental or psychiatric impairment * Cannot understand or provide signed informed consent * Cannot provide verbal or written feedback * Have been implanted with a pacemaker or other active medical device * Must continuously take anticoagulants * Uncontrolled heart or cardiovascular-related disease conditions * Have been diagnosed with muscle atrophy and/or peripheral polyneuropathy

Design outcomes

Primary

MeasureTime frame
Electrophysiological integrity of the nerves surrounded by the nerve cuffs assessed using Nerve Conduction Velocity (NCV) tests. Status Quo in physical examinations of the subject.Throughout the study period (23 weeks)

Secondary

MeasureTime frame
Ability to stimulate the common peroneal nerve and selectively activate ankle dorsiflexor muscles to produce symmetrical motion of the foot. Ability to sense the heel-strike and toe-lift events during walking.From the surgical implantation to the end of the study (i.e. 20 weeks)

Countries

Canada, India, United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026